Loading, Please Wait...
WALTHAM, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the appointment of Eric Kimble as Chief Commercial Officer. Mr. Kimble will be responsible for the design and execution of a global commercial strategy, including sales and marketing operations.
“We are very pleased to welcome Eric to our team as we prepare to commercialize our lead clinical assets, ETX2514SUL and zoliflodacin,” commented Manos Perros, Chief Executive Officer of Entasis Therapeutics. “Entasis has reached a pivotal moment with the recent launch of ATTACK, our Phase 3 clinical trial of ETX2514SUL, and the planned launch of the Phase 3 clinical trial of zoliflodacin in collaboration with our partner, the Global Antibiotic Research and Development Partnership (GARDP) in mid-2019. Eric’s commercial leadership experience with CUBICIN®, as well as his customer-centric focus will drive a commercial organization that places patients and providers at the center of everything we do at Entasis.”
Mr. Kimble is an accomplished life sciences executive with over 25 years of experience in sales, marketing and commercialization. Before joining Entasis Therapeutics as an employee, he worked on a consulting basis for the Company, as well as for several other antibiotic companies. Previously, he held various leadership roles at Cubist Pharmaceuticals, including VP of Sales and Marketing during the accelerated growth phase of CUBICIN, and VP of Program and Portfolio Management. Mr. Kimble has held various sales and marketing positions at Biogen Inc. and Merck & Co. and began his career in management consulting at Arthur D. Little, Inc. Mr. Kimble earned his M.B.A. from Harvard University and his bachelor’s degree as a double major in English Literature and Business Economics from Brown University.
“The Centers for Disease Control has identified multidrug-resistant Acinetobacter, carbapenem-resistant Enterobacteriaceae (CRE), and drug-resistant Neisseria gonorrhoeae as three of the bacterial pathogens that pose dangerous antibiotic resistance threats in the United States,” said Mr. Kimble. “Entasis’s pipeline addresses all three of these specific pathogens, and I welcome the challenge of commercializing antibiotics in an environment that demands value for patients and the providers that serve them.”
CUBICIN® is a registered trademark of Merck Sharp & Dohme Corp.
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.
Entasis Company Contact
Investor Relations Contact
The Ruth Group
The Ruth Group